Subsequent Events (Details) - USD ($) |
1 Months Ended | 3 Months Ended | ||
|---|---|---|---|---|
Apr. 10, 2023 |
Apr. 19, 2023 |
Mar. 31, 2023 |
Dec. 31, 2022 |
|
| Subsequent Events (Details) [Line Items] | ||||
| Exercise price | $ 0.0001 | |||
| Common stock, par value | 0.0001 | $ 0.0001 | ||
| Purchase price per share | $ 1.6 | |||
| Warrant expiration | 7 years | |||
| Aggregate price (in Dollars) | $ 5,000,000 | |||
| Subsequent Event [Member] | ||||
| Subsequent Events (Details) [Line Items] | ||||
| Cash fee (in Dollars) | $ 40,000 | |||
| Fair market value (in Dollars) | $ 100,000 | |||
| Grant vesting anniversary | 1 year | |||
| Issuance of options (in Shares) | 58,100 | |||
| Exercise price | $ 1.73 | |||
| Aggregate consideration (in Dollars) | $ 11,999,999.29 | |||
| Aggregate shares sold (in Shares) | 3,125,000 | |||
| Common stock, par value | $ 0.0001 | |||
| Purchase price per share | $ 1.6 | |||
| Purchase of common stock (in Shares) | 1,875,069 | |||
| Subsequent Event [Member] | Warrant [Member] | ||||
| Subsequent Events (Details) [Line Items] | ||||
| Exercise price | $ 1.75 | |||
| Purchase price per share | $ 0.0001 | |||
| Purchase of common stock (in Shares) | 4,375,273 |
| X | ||||||||||
- Definition Aggregate price. No definition available.
|
| X | ||||||||||
- Definition Grant vesting anniversary. No definition available.
|
| X | ||||||||||
- Definition Purchase of common stock. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Cash Flows between a transferee and a transferor attributable to servicing fees related to a securitization, asset-backed financing arrangement, or similar transfer in which the transferor has continuing involvement with the transferred financial assets underlying the transaction (including, but not limited to, servicing, recourse, and restrictions on transferor's interests in the transferred financial assets). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Face amount or stated value per share of common stock. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of excess stock shares of an entity that have been sold or granted to shareholders. No definition available.
|
| X | ||||||||||
- Definition Amount of gain (loss) from (increase) decrease in fair value of contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk. Excludes change attributable to instrument-specific credit risk. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Cash received on stock transaction after deduction of issuance costs. No definition available.
|
| X | ||||||||||
- Definition The number of shares issued or sold by the subsidiary or equity method investee per stock transaction. No definition available.
|
| X | ||||||||||
- Definition Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|